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Background: Cell lines have been widely used in biomedical research. The community-based Cell Line Ontology (CLO)
is a member of the OBO Foundry library that covers the domain of cell lines. Since its publication two years ago,
significant updates have been made, including new groups joining the CLO consortium, new cell line cells, upper
level alignment with the Cell Ontology (CL) and the Ontology for Biomedical Investigation, and logical extensions.
Construction and content: Collaboration among the CLO, CL, and OBI has established consensus definitions of cell
line-specific terms such as ‘cell line’, ‘cell line cell’, ‘cell line culturing’, and ‘mortal’ vs. ‘immortal cell line cell’. A cell
line is a genetically stable cultured cell population that contains individual cell line cells. The hierarchical structure of
the CLO is built based on the hierarchy of the in vivo cell types defined in CL and tissue types (from which cell line
cells are derived) defined in the UBERON cross-species anatomy ontology. The new hierarchical structure makes it
easier to browse, query, and perform automated classification. We have recently added classes representing more
than 2,000 cell line cells from the RIKEN BRC Cell Bank to CLO. Overall, the CLO now contains ~38,000 classes of
specific cell line cells derived from over 200 in vivo cell types from various organisms.
Utility and discussion: The CLO has been applied to different biomedical research studies. Example case studies
include annotation and analysis of EBI ArrayExpress data, bioassays, and host-vaccine/pathogen interaction. CLO’s utility
goes beyond a catalogue of cell line types. The alignment of the CLO with related ontologies combined with the use
of ontological reasoners will support sophisticated inferencing to advance translational informatics development.
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Cell culturing dates back to as early as 1911 when Alexis
Carrel attempted to grow living cells outside an organ-
ism. The establishment of the first human cell line,
HeLa, in 1951 has since brought the fruitful develop-
ment of other cell lines from different organisms. Cell
lines have been commonly used in many aspects of bio-
medical research and experimentation. Mass production
of cell line culture of animal cells is fundamental to the
manufacture of viral vaccines and other products in bio-
technology such as enzymes, synthetic hormones, anti-
cancer agents, and immunobiologicals (e.g., monoclonal
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reproduction in any medium, provided the orhas been realized that cell lines are often contaminated by
other lines – for example, the robust HeLa line has been
shown to have widely contaminated many cell lines [1-3].
In addition to the cross-contamination, other issues
exist in the domain of cell line representation. Due in
large part to a history of bottom-up naming practices,
cell line nomenclature has not been standardized or con-
trolled by any centralized authority. This has made man-
agement and tracking of cell line information a difficult
task, despite the existence of various public repositories
and indexed catalogues available for open access. More-
over, cell line related terms are loosely interchangeable
and inconsistently used across communities, such that
terms like ‘primary cells’, ‘primary cell culture’, and ‘cell
line’ have become loaded with conflated and ambiguous
meaning. Confusion can also come from variability in
how cell lines are categorized. This results in part fromral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cell lines confer diverse attributes used in their clas-
sification. As we move toward the establishment of a
centralized resource for cell lines, the ambiguity of cell
line-associated terms needs to be clarified.
Many of the challenges can be addressed by the devel-
opment of an ontology for cell lines, wherein the various
cell line attributes can be normalized and based on
agreement between users in the community. The dif-
ferent aspects of describing a cell line can be modu-
larized by their corresponding source organism and
anatomical part, modifications, and culturing methods,
or related diseases.
The Cell Line Ontology (CLO) is a community-based
ontology that covers the biological cell line domain. The
CLO was originally presented in the International Con-
ference on Biomedical Ontology (ICBO) in 2011 [4].
The original CLO was developed cooperatively by ontol-
ogy editors from the University of Michigan Cell Line
Knowledge base (CLKB) team, the EBI Functional Gen-
omics Production Team, Cell Ontology (CL) [5] team,
and the Bioassay Ontology (BAO) development team at
the University of Miami. Subsequently, the Cell Bank of
RIKEN BioResource Center (BRC) in Japan, the Ontology
for Biomedical Investigation [6], and Reagent Ontology [7]
joined the CLO development consortium. The CLO Con-
sortium aims to unify publicly available cell line data from
multiple sources to a standardized format based on a con-
sensus design pattern derived from the establishment of
CLO. This manuscript focuses on introducing recent up-
dates on the CLO development.
Construction and content
CLO statistics
The development of CLO follows the OBO Foundry
principles, including openness, collaboration, and use of
a common shared syntax [8]. As a result, the CLO devel-
opers have been working to establish a common under-
standing and agreement of key CLO-specific terms. The
CLO terms and definitions have been created and re-
fined with the input from participants who utilize the
CLO in their studies. In addition, the CLO also makes
use of existing ontologies via an OntoFox import strategy
[9]. The CLO is aligned with the Basic Formal Ontology
(BFO; http://www.ifomis.org/bfo) version 2 (Graz release)
by importing of all the class terms of BFO as its upper level
ontology. Note that the preparation for BFO version 2.0
alignment has also been implemented in the event that its
use becomes an OBO recommendation. Object properties
imported from the Relation Ontology (RO) are used to
represent relations in the CLO. Some terms from Spatial
Ontology (BSPO), SemanticScience Integrated Ontology
[10] and Information Artifact Ontology (IAO) [11] are also
imported as part of the top-level ontology manager. Table 1summarizes classes imported for the upper-level ontology
operations, along with the classes utilized from other exter-
nal ontologies to establish data integration and to support
automated reasoning.
In summary, CLO consists of over 38,000 terms for
various cell line cells. These are mostly cell line informa-
tion obtained from cell line records deposited at four cell
line resources: the ATCC and HyperCLDB cell lines
stored in the CLKB from the University of Michigan,
Corriell Cell Lines processed by EBI, and the cell lines
from the Cell Bank of RIKEN BioResource Center (BRC).
Almost 300 cell line entry descriptors of cell types were
imported from CL and over 1,300 anatomical entities were
imported from UBERON [12]. CLO currently contains in-
formation of cell lines derived from more than 350 species
(NCBITaxon entities). Biomedical experiment related
terms were imported from OBI and EFO [13]. When
applicable, components from the following resources: Gene
Ontology (GO), Phenotypic Quality Ontology (PATO),
Protein Ontology (PRO) [14], Chemical Entity of Biological
Interest (ChEBI), and Human Disease Ontology (DOID)
are imported into CLO based on available information in
the cell line cell records.
The CLO was developed using the format of W3C
standard Web Ontology Language (OWL2) (http://www.
w3.org/TR/owl-guide/). The latest CLO is available for
public view and download at http://code.google.com/p/
clo-ontology/. The latest version of the CLO is also avail-
able for visualization and downloading from Ontobee
(http://www.ontobee.org/browser/index.php?o=CLO) or
NCBO’s BioPortal: (http://purl.bioontology.org/ontology/
CLO). The source code of CLO is open and freely available
under the Apache License 2.0.
Alignment of core domain concepts between CLO, OBI,
and CL
As part of the CLO refactoring process, a working group
was established between members of several key open
biomedical ontologies where cell line-related entities are
represented, including the Cell Ontology (CL) and the
Ontology for Biomedical Investigation [6]. The goal of
this group was to align modelling related to cultured
cells in accordance with OBO Foundry principles of or-
thogonality and re-use. One key outcome of this work
was the integration of inconsistent representations into a
single shared model. Classes representing key concepts
were implemented in the CL, CLO, and OBI - with the
CL as a home for high-level in vitro cell modelling (e.g.
cultured cell), the CLO as a home for more specific cell
line cell and cell line classes, and the OBI as a home for
experimental entities related to these cell lines (e.g. cell
line culture and establishing cell line classes). As a result,
each term has a single representation that is re-used be-
tween ontologies through established import mechanisms.
Table 1 Summary of ontology terms in CLO and major source ontologies used in CLO as of November 21st, 2013
Ontology Classes Object properties Annotation properties Total
CLO (Cell Line Ontology) specific 38453 2 0 38455
Imported upper-level ontologies
BFO (Basic Formal Ontology) 22 38 0 60
RO (Relation Ontology) 0 85 1 86
BSPO (Spatial Ontology) 0 18 0 18
SIO (SemanticScience Integrated Ontology) 0 3 0 3
IAO (Information Artifact Ontology) 17 2 17 36
Imported entities from other external ontologies
OBI (Ontology for Biomedical Investigation) 20 6 2 28
EFO (Experimental Factor Ontology) 149 1 1 151
CL (Cell Ontology) 269 0 0 269
UBERON 1315 0 0 1315
NCBITaxon (NCBI Taxonomy) 354 0 0 354
PATO (Phenotypic Quality Ontology) 22 0 0 22
GO (Gene Ontology) 299 0 0 299
PR (Protein Ontology) 5 0 0 5
DOID (Human Disease Ontology) 741 0 0 741
ChEBI (Chemical Entities of Biological Interest) 32 0 0 32
Total 41698 155 21 41874
The detail of total number of terms and the most recent update can be viewed at http://www.ontobee.org/ontostat.php?ontology=CLO.
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crafting of clear consensus definitions for common but
ambiguous domain terminology, including a careful
characterization of the term 'cell line' itself. Updated
definitions for a selection of key CLO classes resulting
from this work are detailed below.
A cell line is defined as a genetically stable and
homogenous population of cultured cells that shares a
common propagation history (i.e. has been successively
passaged together in culture). This view clarifies two key
confusions surrounding the term ‘cell line’. The first re-
lates to the scale at which the term applies, here refer-
ring to discrete experimental populations rather than
maximal collections representing an entire lineage (e.g.
the collection of all HeLa cells that exist). The second
concerns the criteria that establish when a cultured cell
population qualifies as a ‘line’. By applying ‘cell line’ to
experimental populations with a shared culture history,
we define the term consistently with its most prevalent
usage in domain discourse, and in a way that is most fit
for data annotation needs, as it represents populations
that are actually cultured, experimented upon, and shared
in the practice of science.
A cell line cell is defined simply as a cultured cell that
is part of a cell line. This class is a child of CL:cultured
cell, defined as a cell in vitro that is or has been cultured
in vitro (Figure 1). Cell line cells, like cell lines, can existin active culture or stored in quiescence. The represen-
tation of each specific cell line (e.g. HeLa, HEK293) is
implemented at the scale of individual cells, such that
‘cell line cell’ is the root of the core CLO hierarchy of
cell line types.
A clonal cell line is defined as a cell line that derives
from a single cell that is expanded in culture. Feedback
from community experts and stakeholders initiated the
representation of this specific type of cell line as a key ex-
perimental resource with unique and valuable attributes.
Finally, a cell line culture represents an actual physical
culture of cell line cells that is an input to experimental
processes, and is comprised cell line cells and the media
along with any added components. This term is intended
to cover actively propagated cultures as well as those
kept frozen.
Through the alignment efforts summarized above, we
have increased the utility of the CLO as a community
resource for standardizing reference to domain concepts
and facilitating the exchange and discovery of cell line
related information.
Basic CLO cell line design pattern
The basic CLO design pattern represents organ anat-
omy, cell types, disease and pathology, source informa-
tion in the form of ownership and derivation where cell
lines are related to each other, and technical information
Figure 1 The top level CLO hierarchical structure and key ontology terms. Terms imported from other ontologies are indicated by the
ontology abbreviations inside parentheses. Terms without an identified source are CLO terms. All the arrows indicate the ‘is_a’ relation except the
explicitly labelled ‘has grain’ relation.
Sarntivijai et al. Journal of Biomedical Semantics 2014, 5:37 Page 4 of 10
http://www.jbiomedsem.com/content/5/1/37such as culture conditions (Figure 2A). A core design
pattern implemented for, cell line cell, describes deriv-
ation from an in vivo cell, which is in turn, part of some
anatomical structure, and in turn, anatomical structure
is part of a species of organism. In addition, diseases
borne by the source organism can be captured in this
pattern when known. An object property ‘is model for’ is
defined to represent a relation between a cell line cell
and a disease where the cell line cell is a model system
for studying the disease. An example of applying this
general design pattern to a concrete example is shown
in Figure 2B where the design pattern is used to repre-
sent a HeLa cell transfected with luciferase reporter in
BAO. In this example, a HeLa cell transfected with a lu-
ciferase reporter ‘derives from’ HeLa cell through a
stable transfection that ‘is a’ cell line cell modification
process. The transfected HeLa cells are part of or speci-
fied input of cell line culturing process, specifically, ad-
herent cell line culturing process. This cell line cell also
inherits the pathological cell properties from HeLa cell
(as a cell line cell), which ‘derives from’ some epithelial
cell that is ‘part of ’ some uterine cervix, which is ‘part of ’
an organism Homo sapiens. This specific instance of
Homo sapiens also ‘has disease’ of some cervical carcin-
oma, which ‘is a’ carcinoma and HeLa cell is a cell line
model for studying this cancer. Relations of knowledge
in multiple domains are shown in this example of a cell
line cell annotation in BAO with the semantic infra-
structure provided by CLO. Modification of a cell line
cell can give rise to another derived cell line cell, which
is also described by ’derives from’ relation. A cell line
cell is specified input of some special culturing process
(CLO:cell line cell culturing, a subclasss of OBI:maintaining
a cell line culture), which can differ from culturing one cellline cell to another (e.g., suspension cell line culturing
or adherent cell line culturing). The relation ‘derives
from’ is not a transitive relation. The ‘derives from’ re-
lation could be transitive if, and only if, there are no
confounding environmental and/or experimental con-
ditions that affect the cell line’s characteristics (such
as cross contamination). The cell line cell culturing re-
flects a particular culturing condition or growth mode
(e.g. suspension or cell surface adhesion). A cell line is
supplied, maintained, or catalogued by a specific organi-
zation such as American Type Cell Culture (ATCC) that
‘has cell line repository role’. Since relation terms such as
‘supply, ‘own’, or ‘manage’ have not been fully developed
in any ontology, we have created a CLO-specific relation
reflecting this activity with the label ‘is in cell line reposi-
tory’. This object property designates the representation
of a particular cell line’s information in such repository.
This is an update from the previous version that utilized
relation ‘mentions’ to describe this activity. The relation
of class label ‘mentions’ was used in CLO’s previous re-
lease to cover all general references to a source, such as
MeSH, as CLO made use of MeSH entries that neither
supplied, owned, nor catalogued, but rather just listed
(or mentioned) cell lines instead. In this version of
CLO, MeSH reference was established via ‘seeAlso’ an-
notation property value.
The basic design model can be extended in different
aspects. In addition to having an organism acting as a
‘bearer of ’ a cancer, or a disease, the Coriell cell line re-
pository has often provided the information that associ-
ates a cell line to a specific disease using the relation ‘is
model for’. With this relation, there is no need to con-
nect a cell line to a disease through the organism. One
drawback of directly applying this design pattern is that
Figure 2 CLO cell line design pattern and an example. (A) Generic CLO design pattern. Terms imported from external ontologies are displayed
in blue boxes, while CLO-specific terms are displayed in yellow boxes. (B) An example of HeLa cell representation by applying CLO design pattern
with extended information obtained from the BAO development (shown in dashed orange boxes) with details of culturing method, cell line
modification, and STR profiling. Boxes represent instances, some labelled by the class they are an instance of. The relations used to link the
boxes are instance-level relations. In several cases the parent class is also noted in the box using an is_a relation.
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mostly one-layer with one level of subclassing where
majority of the cell line cell classes are all immediate
children of the parent class ‘mortal’ or ‘immortal’ cell
line cell. Logical reasoning is the primary approach to
infer a possible hierarchy. However, such inferential rea-
soning of this one-level subclassing information ap-
proach is not optimal as the scalability of computational
resources and power can be problematic in processing a
large ontology. Another possibility to ease the situation
is to introduce a pre-composed differentia criteria asser-
tion for classification. However, if we consider pre-
composing all possible differentia parents in CLO (e.g.
by organism, by cell type, by anatomical entity, or by
culturing methods), construction of an asserted hier-
archy based on all criteria will lead to scalability andmaintenance issues and, we would face the situation of
exponential growth of the pre-composed differentia par-
ent hierarchy and risks the generation of logical, but bio-
logically nonsensical class creation. A proposal for the
solution to overcome this challenge has been addressed
in the updated version as outlined below.
Restructuring of cell line cell hierarchy
There are approximately 38,000 immortal cell line cells
in the CLO. To list them all as a single layer under im-
mortal cell line cell is problematic. For example, a one-
layer structure would miss a classification that may be
useful to have as intermediate layer terms (e.g., immortal
epithelial cell), which have been frequently used. These
intermediate layer terms need to be added to the CLO,
and specific cell lines can be asserted under these terms
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added, specific cell line cell terms can be asserted to
under these intermediate terms, supporting effective query
and data analysis. The accurately asserted hierarchy can
also prevent time consuming reasoning process given the
large number of cell line cells in the CLO.
To solve these issues, the updated CLO includes a
new multi-layer hierarchical structure based on well-
defined design patterns, making it easier to browse, query,
and perform automated classification. The hierarchical
structure of cell line cells in the CLO is built up primarily
based on three criteria: in vivo cell type, in vivo tissue
types, and organism species, from which cell line cells are
derived. Currently all cell line cells in the CLO are immor-
tal, so the term ‘immortal’ is used in all the intermediate
cell line cell terms. We first used specific cell types defined
in the CL to generate cell type specific cell line cells, e.g.,
immortal fibroblast cell line cell. The CLO contains 271
cell type terms imported from the CL (Table 1). New CLO
terms defined based on CL cell types follow the same hier-
archical structure of corresponding CL terms. Secondly,
we added an anatomical region (e.g., liver), defined in
UBERON, to the specific cell line to generate an organ-
specific term, i.e., immortal liver-derived fibroblast cell line
cell. CLO currently contains over 1,300 anatomical struc-
ture terms imported from UBERON (Table 1) and used
for this process. Lastly, the organism species (e.g., Homo
sapiens defined by NCBITaxon) was used to generate an
organism-specific intermediate layer, e.g., immortal human
liver-derived fibroblast cell line cell. The CLO includes
cell line cells originated from over 100 different animal
species. In total, we have generated over 1,000 intermedi-
ate classes in CLO.
To better illustrate the restructuring strategy, the
HeLa-related hierarchy is used as an example (Figure 3).
Five intermediate terms were generated between ‘HeLa
cell’ and ‘immortal cell line cell’ (Figure 3A). To auto-
matically generate these intermediate layers, three Java
programs were developed internally to use the following
axiom defined for the HeLa cell (Figure 3B):
'derives from' some
('epithelial cell'
and ('is part of' some ('uterine cervix'
and ('is part of' some 'Homo sapiens'))))
The ‘epithelial cell’ (CL_0000066) defined in the CL
includes parent terms ‘animal cell’, ‘eukaryotic cell’, and
then ‘native cell’. Based on this hierarchy, the CLO in-
cludes the first three layers of superclasses of ‘HeLa cell’
under ‘immortal cell line cell’ (Figure 3A). Based on the
UBERON ‘uterine cervix’ linkage, a new term ‘immortal
uterine cervix-derived epithelial cell line cell’ is generated.
Lastly, the term ‘immortal human uterine cervix-derivedepithelial cell line cell’ is generated as a new immediate
superclass of ‘HeLa cell’ (Figure 3A). It is noted that the
CLO includes a new term called ‘immortal human epithe-
lial cell line cell’ that is not an asserted superclass of the
‘immortal uterine cervix-derived epithelial cell line cell’
(Figure 3A). However, a reasoning process infers such an
is_a relation (Figure 3C), based on the related equivalent
class definitions (Figure 3D and E).
Adding new cell line cells in Japan RIKEN Cell Bank
to CLO
RIKEN cell lines are associated with unique IDs man-
aged in the BioResource Web Catalog (http://www.brc.
riken.jp/lab/cell/english/search.shtml). When integrating
these cell lines into CLO, they are merged and assigned
new CLO IDs. First, an Excel worksheet with a fixed
template was generated to represent 1622 cell lines from
the Riken Cell Bank. It is noted that these cell lines do
not include any stem cells stored in the RIKEN Cell
Bank. The data prepared in the worksheet was used as
input for the Ontorat tool to generate an OWL file that
can be directly imported and merged to CLO. The
Ontorat program (http://ontorat.hegroup.org/) [15] acts
by following ontology design patterns. Specifically, the
immediate parent terms of individual RIKEN cell line
cells were manually identified based on the reconstructed
cell line cell hierarchy described above, and inserted into
the Excel worksheet. A new CLO 'label' was generated
by combining a unique RIKEN cell line number (e.g.,
RCB0871) with the word 'cell', for example, 'RCB0871
cell'. The RIKEN cell line names are defined as alternative
terms. Other information such as cell line originators
and registers are also included in the CLO annotations
for these new RIKEN cell lines.
Utility and discussion
CLO applications
Cell lines are routinely used in various biological and
biomedical studies. For example, many cell lines have been
used as models for analysis of in vivo host -pathogen inter-
actions and vaccine-induced cellular immune responses.
Brucellosis is one of the most common zoonotic infectious
diseases in humans and other animals worldwide. Brucel-
losis is caused by virulent Brucella, an intracellular bacter-
ium that replicates and survives inside macrophages.
Virulent Brucella strains, including B. abortus strain 2308,
survive inside macrophages and inhibit macrophage cell
death for prolonged replication. However, the live at-
tenuated B. abortus cattle vaccine strain RB51 triggers
(positively regulates) programmed cell death of RAW264.7
cell, a macrophage cell line cell used for in vivo cell model-
ling [16]. Further study found that a cell death in the cell
line cells is mediated by caspase-2. The infected cell line
cells also undergo different cellular processes including
Figure 3 Demonstration of restructured CLO cell line cell hierarchy and the application of reasoning. (A) asserted HeLa cell hierarchy.
Five intermediate terms between ‘immortal cell line cell’ and ‘HeLa cell’ have been generated in CLO. (B) The SubClass axioms of ‘HeLa cell’.
(C) Part of an inferred CLO hierarchy. Compared to the asserted hierarchy in Figure 3A, the term ‘immortal human uterine cervix-derived epithelial
cell line cell’ has been inferred as a subclass of ‘immortal human epithelial cell line cell’. (D) The equivalent class definition for ‘immortal human
epithelial cell line cell’. (E) The equivalent class definition for ‘immortal human uterine cervix-derived epithelial cell line cell’. The OntoFox tool [9]
was used to generate a subset of CLO that includes HeLa cell-related terms. The screenshots were generated using the Protégé OWL editor. The
ELK version 0.3.2 ontology reasoner was used for reasoning.
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terial replication [16,17] (Figure 4). The phenotypes shown
in vitro using cell line cells could also be verified in vivo
and using primary macrophages directly isolated from
mouse [16].
The European Bioinformatics Institute (EBI) Functional
Genomics Group has developed ArrayExpress and an
ontology-based linked data system for direct processing
and query of microarray data from different studies,Figure 4 CLO application in modelling the cell line cell-vaccine/patho
B. abortus cattle vaccine strain RB51 positively regulated programmed cell
type virulent strain 2308 negatively regulated the programmed cell death.
interaction with the vaccine or pathogen. All the boxes represent instancesincluding cell line cell studies. Given the usage of cell
lines in microarray studies, the development of a com-
prehensive cell line cell ontology is needed to support for
efficient query of functional genomics studies. EBI has
been using an internally developed Coriell Cell Line
Ontology for ArrayExpress microarray data analysis [18].
Since the contents of the Coriell Cell Line Ontology are
now incorporated into CLO and the CLO structure and
its alignment with existing ontologies have significantlygen interactions. As reported in a reference [16], the live attenuated
death of RAW264.7 cell, a macrophage cell line cell. However, its wild
The infected cells underwent different cellular processes after the
, labelled by the class they are an instance of.
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future array data analysis. A clear CLO use case lies in
the usability of the ArrayExpress database. Researchers
often query cell lines with cross-reference information to
the cell lines’ corresponding tissues and cell types. The re-
constructed CLO intermediate term hierarchy provides an
effective mechanism to support this type of query.
The Bioassay Ontology (BAO) describes bioassays and
results obtained from small molecule perturbations, such
as those in the PubChem database [19]. To describe and
annotate cell-based PubChem assays and screening results
comprehensively, the BAO is being extended through col-
laborative development of the CLO. By integrating the
BAO with the CLO, those cell lines that are typically used
in cellular assays are added into the CLO. Based on the
demands of BAO bioassay modelling, extended parame-
ters are being added to the CLO, including different
sources of cell lines (normal/healthy tissue, pathological
tissue, or tumor), cell modification methods (plasmid
transfection, viral transduction, cell fusion, etc.), culture
conditions (composition of culture medium), morphology
(epithelial, lymphoblast, etc.), growth properties (adherent
or suspension), short tandem repeat (STR) profiling and
other properties that are relevant for cellular screening
[19]. As a demonstration of the use of CLO in BAO
bioassay modelling, the STR profiling analysis with the
HeLa cell line has been modelled in the context of a
PubChem assay (AID 1611) (Figure 2B). In the PubChem
assay, HeLa cells were modified by stable transfection
with a heat shock promoter driven-luciferase reporter
gene construct. In this assay, the modified HeLa cells
were used to screen for compounds that could induce
heat shock transcriptional response as a potential thera-
peutic for Huntington’s disease and amyotrophic lateral
sclerosis (ALS) (http://pubchem.ncbi.nlm.nih.gov/assay/
assay.cgi?aid=1611).
As shown in the use cases above, integrating a formal
representation of cell lines will benefit researchers in
interpreting and analysing host-pathogen interactions
and cell-based screening results, and better understand-
ing the mechanisms of genotype-phenotype mappings.
Formally described cell lines and related experimental
conditions can help researchers better understand cellu-
lar and immunological pathways, and support rational
design of novel assays, for example, with respect to choos-
ing the best cellular model system, in identifying which
modified cell lines are available and in demonstrating
which ones work best in existing assays.
Discussion and perspectives
The initial attempt to represent cell line information sys-
tematically in the CLKB has been performed by impos-
ing ontological semantics and structure on the CLKB
and transferring it to the CLO. The CLO now provides abetter organization of cell line related information. This,
in turn, aids further ontology application in modern
translational bioinformatics, especially in the domain of
concept mapping and alignment to represent knowledge
in a complex biological system. As shown in this paper,
contributions by the community collaborators have
customized the CLO to accommodate the various use
cases in the biomedical domain. The CLO aligns with
existing OBO Foundry ontologies including CL, OBI, and
UBERON. The governance of the CLO is achieved by
importing upper-ontology classes from other OBO Foun-
dry ontologies, namely, BFO, RO, OBI, and OGMS. Based
on the alignment and new CLO design pattern, intermedi-
ate cell line cell terms were generated and new cell line
cells from Japan RIKEN Cell Bank were included in the
CLO. This paper also introduces many use cases utilizing
CLO ontological features.
The recent development of the Cell Culture Ontology
(CCONT) has resulted in an ontology with overlapping
cell line information to CLO [20]. CCONT inherits a
parent cell line definition from the Experimental Factor
Ontology (EFO) [13] that describes a cell line as a popu-
lation of cells cultured in vitro. This shifts the focus of
cell line representation from biologically-defined individ-
ual cells to the experimental perspective of a cell line
population culturing description. CCONT has not yet
aligned with CL and OBI and intermediate terms of tis-
sue and organism have not been implemented. CCONT,
however, introduces many useful cell line-associated
properties such as safety classification and cytogenetics.
With the complementary components to describe a cell
line related information shared between the CLO and
CCONT, it is possible that future collaboration may be ini-
tiated for the benefit of the community.
The current primary focus of the CLO does not yet
encompass the consideration of stem cell derived cell
lines. A generally accepted definition of a stem cell line
is a self-renewing population of cells with the ability to
differentiate into multiple distinct cell types [21]. In this
definition, human stem cells have their origin in a var-
iety of cell types ranging from pluripotent cells derived
from embryos (human embryonic stem cell – hESC) to
adult stem cells derived from various fully developed tis-
sues such as blood, or bone marrow. The ability to dif-
ferentiate into distinct cell types is more limited in adult
stem cells in comparison to the pluripotency in hESC. In
addition to having multiple cell type origins, stem cells
can also differentiate into multiple distinct cell types
under different conditions. Therefore, defining stem cell-
derived cell lines based on their origin tissue/cell where
they are created (as mandated by CLO’s design pattern)
may not be sufficient to yield the information that ex-
perimental researchers need. Compared to stem cells,
regular immortal cell line cells have largely unchanged
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The issues surrounding the correct ontological representa-
tion of stem cell line cells are currently under investigation
at a community level.
Confusion created by mislabelling/misidentification due
to cross contamination and naming ambiguity has led to
the need for cell line authentication and management,
especially when cell lines are used as disease models
in drug-discovery screening projects. A few attempts
to resolve the situation have been introduced to the
community. The ATCC initiated the ATCC Standards
Development Organization (ATCC SDO) in 2007, lead-
ing to new consensus standards to authenticate cell lines
by short tandem repeat (STR) DNA profiling (http://
www.atcc.org/~/media/PDFs/STR_Profiling.ashx). Al-
though STR profiling provides an online service for
human cell line authentication, there exists no unified
cataloguing data source that lends itself as a structured
information system with the ontological capability to
manage the information, transfer knowledge, and assist
in knowledge discovery. We expect that a future collab-
oration between the CLO , the ATCC and other partners
will provide a more effective way to support such an
effort.
The CLO will contribute to the wider dissemination of
cell line information for improving access and promoting
the common use of cell lines as biological resources. Re-
cently, “Linked Open Data (LOD)”, a set of methodologies
for exposing, sharing, and connecting pieces of data, infor-
mation, and knowledge on the World Wide Web (WWW)
using URI and Resource Description Framework (RDF)
coding has been proposed as a strategy forming the col-
lective intelligence by the integration of data throughout
the entire Internet. The CLO is fully compatible with the
LOD strategy and has the potential to promote wider dis-
semination, easier use in local data analyses, and the ex-
pansion of public data sources by enabling distributed
(non-centralized) efforts by the user community for cell
line data. In RIKEN, the RDF/OWL based integrated data-
base (SciNetS: https://database.riken.jp/) [22] and open
data archive (BioLOD: http://www.w3.org/wiki/HCLSIG/
LODD/Data), will utililize CLO for the data format of cell
lines. Furthermore, the coordinating efforts in CLO devel-
opments with other biomedical ontologies such as those in
the OBO Foundry will promote broader integration of cell
line information with other domains in life science.
Conclusions
Capabilities embedded within the CLO’s structure facili-
tate knowledge transfer and discovery that a simple cata-
logue of cell line cells could not achieve. Automated
reasoning and alignment with other related ontologies
study will expand the network of knowledge much needed
for the future translational informatics development. Notonly will the ontology backbone of CLO assist in this de-
velopment, but the uniform knowledge base of over 38,000
cell line cells in CLO also makes CLO a reference resource
for translational informatics. Ambiguity introduced by
mislabelling of cell lines from various factors can also
be minimized by using the CLO as a reference. A uni-
form representation of each cell line’s properties along
with the curation of verifying information from other
knowledge sources will minimize errors in experimen-
tal reporting.
The CLO Consortium initiative is the first collabora-
tive attempt among our partner institutes as listed here
to facilitate cell line data discovery and knowledge trans-
fer to aid integrative translational biomedical research.
As the CLO is an on-going community-driven project, it
will continue to grow and evolve to overcome challenges
that surface in the translational domain. We encourage
all parties to participate by contributing their domain
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